Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07476118 · ClinicalTrials.gov registry record · Phase 1
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
A Phase 1 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT07476118 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 150 participants.
The verdict
NCT07476118, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks.
Interventions
- OTHER Placebo
- DRUG Brenipatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07476118
The ClinicalTrials.gov registry entry for NCT07476118 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07476118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07476118 about?
NCT07476118 is a clinical study titled "A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity". The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will las...
What is the current status of trial NCT07476118?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2026-03-18. Estimated completion is 2027-02.
What interventions are being tested in trial NCT07476118?
The interventions under investigation include: Placebo (OTHER), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07476118?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.